ES2565063T3 - Anticuerpos para el tratamiento de un cáncer que expresa la claudina 6 - Google Patents
Anticuerpos para el tratamiento de un cáncer que expresa la claudina 6 Download PDFInfo
- Publication number
- ES2565063T3 ES2565063T3 ES12715856.6T ES12715856T ES2565063T3 ES 2565063 T3 ES2565063 T3 ES 2565063T3 ES 12715856 T ES12715856 T ES 12715856T ES 2565063 T3 ES2565063 T3 ES 2565063T3
- Authority
- ES
- Spain
- Prior art keywords
- cancer
- cell
- carcinoma
- tumor
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title description 25
- 201000011510 cancer Diseases 0.000 title description 13
- 102000003859 Claudin-6 Human genes 0.000 title 1
- 108090000229 Claudin-6 Proteins 0.000 title 1
- 210000004027 cell Anatomy 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 102100038449 Claudin-6 Human genes 0.000 description 8
- 101000882898 Homo sapiens Claudin-6 Proteins 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 208000009956 adenocarcinoma Diseases 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 4
- 208000000453 Skin Neoplasms Diseases 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 206010027540 Microcytosis Diseases 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 231100000588 tumorigenic Toxicity 0.000 description 3
- 230000000381 tumorigenic effect Effects 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 208000001608 teratocarcinoma Diseases 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 208000036652 Adenocarcinoma of the small intestine Diseases 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 208000033133 Testicular seminomatous germ cell tumor Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 208000003373 basosquamous carcinoma Diseases 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 201000010279 papillary renal cell carcinoma Diseases 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 208000004333 pleomorphic adenoma Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 206010073373 small intestine adenocarcinoma Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 208000002918 testicular germ cell tumor Diseases 0.000 description 1
- 208000024662 testicular seminoma Diseases 0.000 description 1
- 208000004238 testicular teratoma Diseases 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Anticuerpo que comprende: (i) una cadena pesada de anticuerpo que comprende una secuencia de cadena pesada de anticuerpo de SEC ID nº 36, y (ii) una cadena ligera de anticuerpo que comprende una secuencia de cadena ligera de anticuerpo seleccionada de entre SEC ID nº 35, nº 54 y nº 55.
Description
5
15
25
35
45
55
65
de cáncer preferentemente son aquellas en las que las células tumorales o las células de cáncer expresan CLDN6 y se caracterizan por la asociación de CLDN6 con la superficie celular de las mismas.
Tal como se utiliza en la presente memoria, una "enfermedad tumoral", una "enfermedad de tipo tumoral" o una "enfermedad tumorigénica" se refiere a una enfermedad caracterizada por una multiplicación, proliferación, diferenciación, adhesión y/o migración celulares reguladas de manera aberrante, lo que puede resultar en la producción, o en la tendencia a producir, tumores y/o metástasis tumorales. La expresión "célula tumoral" se refiere a una célula anormal que se multiplica mediante una proliferación celular no controlada rápida y que continúa multiplicándose después de cesar los estímulos que iniciaron la nueva multiplicación.
El término "tumor" se refiere a un grupo anormal de células o a un tejido que crece mediante una proliferación celular no controlada rápida y que continúa creciendo tras cesar los estímulos que iniciaron el nuevo crecimiento. Los tumores muestran una falta parcial o total de organización estructural y coordinación funcional con el tejido normal, y habitualmente forman una masa diferenciada de tejido, que puede ser benigna, premaligna o maligna.
Preferentemente, una "enfermedad tumoral", "enfermedad de tipo tumoral" o "enfermedad tumorigénica" según la invención es una enfermedad de cáncer, es decir, una enfermedad maligna y una célula tumoral es una célula de cáncer. Preferentemente una "enfermedad tumoral", "enfermedad de tipo tumoral" o "enfermedad tumorigénica" se caracteriza por células que expresan CLDN6 y que se caracterizan por la asociación de CLDN6 con la superficie celular de las mismas y una célula tumoral expresa CLDN6 y se caracteriza por la asociación de CLDN6 con la superficie celular.
Una célula que expresa CLDN6 y que se caracteriza por la asociación de CLDN6 con la superficie celular preferentemente es una célula tumoral o una célula de cáncer, preferentemente de los tumores y cánceres indicados en la presente memoria. Preferentemente, dicha célula es una célula diferente de una célula placentaria.
Las enfermedades de cáncer preferentes o cánceres según la invención se seleccionan de entre el grupo que consiste de cáncer ovárico, en particular adenocarcinoma ovárico y teratocarcinoma ovárico, cáncer de pulmón, incluyendo el cáncer de pulmón microcítico (SCLC) y el cáncer de pulmón no microcítico (NSCLC), en particular el carcinoma y el adenocarcinoma pulmonares de células escamosas, cáncer gástrico, cáncer de mama, cáncer hepático, cáncer pancreático, cáncer de piel, en particular el carcinoma de células basales y el carcinoma de células escamosas, melanoma maligno, cáncer de cabeza y cuello, en particular el adenoma pleomórfico maligno, sarcoma, en particular el sarcoma y el carcinosarcoma sinoviales, cáncer de conductos biliares, cáncer de la vejiga urinaria, en particular el carcinoma de células transicionales y el carcinoma papilar, cáncer de riñón, en particular el carcinoma de células renales, incluyendo el carcinoma de células renales de células claras y el carcinoma de células renales papilar, cáncer de colon, cáncer de intestino delgado, incluyendo el cáncer del íleo, en particular el adenocarcinoma del intestino delgado y el adenocarcinoma del íleo, carcinoma embrionario testicular, coriocarcinoma placentario, cáncer cervical, cáncer testicular, en particular el seminoma testicular, teratoma testicular y cáncer testicular embrionario, cáncer uterino, un tumor de células germinativas tal como un teratocarcinoma o un carcinoma embrionario, en particular un tumor de células germinativas del testículo, y las formas metastásicas de los mismos.
Los tipos principales de cáncer de pulmón son el carcinoma de pulmón microcítico (SCLC) y el carcinoma de pulmón no microcítico (NSCLC). Existen tres subtipos principales de carcinoma de pulmón de células no pequeñas: el carcinoma de pulmón de células escamosas, el adenocarcinoma y el carcinoma de pulmón de células grandes. Los adenocarcinomas constituyen aproximadamente el 10% de los cánceres de pulmón. Este cáncer habitualmente se observa periféricamente en los pulmones, al contrario cáncer de pulmón microcítico (SCLC) y el cáncer de pulmón escamoso, los cuales tienden a localizarse más centralmente.
El cáncer de piel es un crecimiento maligno sobre la piel. Los cánceres de piel más comunes son el cáncer de células basales, el cáncer de células escamosas y el melanoma. El melanoma maligno es un tipo grave de cáncer de piel. Se debe a la multiplicación descontrolada de las células pigmentarias denominadas melanocitos.
Según la invención, un "carcinoma" es un cáncer que se inicia en la capa de revestimiento (células epiteliales) de los órganos.
El "carcinoma bronquiolar" es un carcinoma del pulmón que se cree que deriva del epitelio de los bronquiolos terminales, en los que el tejido neoplásico se extiende a lo largo de las paredes alveolares y crece en pequeñas masas dentro de los alveolos. Puede observarse mucina en algunas de las células y en el material en los alveolos, que también incluye células denudadas.
El "adenocarcinoma" es un cáncer que se origina en tejido glandular. Este tejido también es parte de una categoría más grande de tejidos conocida como tejido epitelial. El tejido epitelial incluye piel, glándulas y una diversidad de otros tejidos que revisten las cavidades y los órganos del cuerpo. El epitelio se deriva embriológicamente del ectodermo, endodermo y mesodermo. Para clasificarse como adenocarcinoma, las células no necesitan ser necesariamente una parte de una glándula, con la condición de que presenten propiedades secretorias. Esta forma de carcinoma puede producirse en algunos mamíferos superiores, incluyendo el ser humano. Los adenocarcinomas
22
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486071P | 2011-05-13 | 2011-05-13 | |
| EP11004004 | 2011-05-13 | ||
| EP11004004 | 2011-05-13 | ||
| US201161486071P | 2011-05-13 | ||
| PCT/EP2012/001721 WO2012156018A1 (en) | 2011-05-13 | 2012-04-20 | Antibodies for treatment of cancer expressing claudin 6 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2565063T3 true ES2565063T3 (es) | 2016-03-31 |
Family
ID=47176322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12715856.6T Active ES2565063T3 (es) | 2011-05-13 | 2012-04-20 | Anticuerpos para el tratamiento de un cáncer que expresa la claudina 6 |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US9321842B2 (es) |
| EP (3) | EP2707390B1 (es) |
| JP (3) | JP6276176B2 (es) |
| KR (3) | KR102072183B1 (es) |
| CN (3) | CN107011440B (es) |
| AR (2) | AR086306A1 (es) |
| AU (4) | AU2012258087B2 (es) |
| BR (1) | BR112013029212B1 (es) |
| CA (1) | CA2832174C (es) |
| CY (2) | CY1118608T1 (es) |
| DK (2) | DK3026064T3 (es) |
| ES (1) | ES2565063T3 (es) |
| HK (1) | HK1195320A1 (es) |
| HR (2) | HRP20160212T1 (es) |
| HU (1) | HUE028603T2 (es) |
| IL (1) | IL228738B (es) |
| LT (1) | LT3026064T (es) |
| ME (1) | ME02369B (es) |
| MX (4) | MX341147B (es) |
| NZ (3) | NZ724296A (es) |
| PL (2) | PL2707390T3 (es) |
| RS (2) | RS58087B1 (es) |
| RU (1) | RU2676731C2 (es) |
| SG (1) | SG193551A1 (es) |
| SI (2) | SI2707390T1 (es) |
| SM (1) | SMT201600064B (es) |
| UA (2) | UA115969C2 (es) |
| WO (1) | WO2012156018A1 (es) |
| ZA (1) | ZA201307102B (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011005630A (es) | 2008-11-28 | 2011-09-28 | Solazyme Inc | Producción de aceites específicos en microorganismos heterótroficos recombinantes. |
| CN107028969A (zh) | 2009-02-20 | 2017-08-11 | 加尼梅德药物公司 | 用于癌症诊断和治疗的方法和组合物 |
| LT2499161T (lt) | 2009-11-11 | 2017-11-27 | Ganymed Pharmaceuticals Gmbh | Specifiniai antikūnai, skirti klaudinui 6 (cldn6) |
| EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| NZ724296A (en) | 2011-05-13 | 2020-05-29 | Ganymed Pharmaceuticals Ag | Antibodies for treatment of cancer expressing claudin 6 |
| KR102134088B1 (ko) | 2012-08-24 | 2020-07-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 |
| WO2015014376A1 (en) * | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| KR20160070191A (ko) | 2013-11-06 | 2016-06-17 | 스템센트알엑스 인코포레이티드 | 신규한 항-클라우딘 항체 및 사용 방법 |
| CN105940107B (zh) | 2013-11-11 | 2021-06-15 | 中外制药株式会社 | 含有改变了抗体可变区的抗原结合分子 |
| JPWO2015108203A1 (ja) * | 2014-01-15 | 2017-03-23 | 株式会社オーダーメードメディカルリサーチ | 抗ｓｌｃ６ａ６抗体を用いたがん治療用医薬組成物 |
| BR112016022727A8 (pt) * | 2014-04-01 | 2018-12-04 | Biontech Cell & Gene Therapies Gmbh | imunorreceptores específicos de claudina-6 e epítopos de células t |
| JP7125248B2 (ja) | 2014-11-11 | 2022-08-24 | 中外製薬株式会社 | 改変された抗体可変領域を含む抗原結合分子のライブラリ |
| CA2966753A1 (en) | 2014-11-17 | 2016-05-26 | Arno Therapeutics, Inc. | Onapristone extended-release compositions and methods |
| CN106146666B (zh) * | 2015-03-26 | 2019-09-06 | 科济生物医药（上海）有限公司 | 靶向cldn6的免疫效应细胞及其制备方法和应用 |
| CN105504051B (zh) * | 2015-12-17 | 2019-08-30 | 北京天成新脉生物技术有限公司 | 狂犬病毒核蛋白单克隆抗体及其应用 |
| EP3474854A4 (en) | 2016-06-27 | 2020-02-19 | The Regents of The University of California | DRUG ASSOCIATIONS FOR THE TREATMENT OF CANCER |
| US20180148471A1 (en) | 2016-11-30 | 2018-05-31 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
| CA3046092A1 (en) * | 2016-12-28 | 2018-07-05 | Genentech, Inc. | Treatment of advanced her2 expressing cancer |
| WO2019048040A1 (en) | 2017-09-06 | 2019-03-14 | Ganymed Pharmaceuticals Gmbh | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
| AU2018334434A1 (en) * | 2017-09-18 | 2020-04-02 | The Regents Of The University Of California | Claudin6 antibodies and methods of treating cancer |
| CN111164208B (zh) | 2017-09-29 | 2023-08-04 | 第一三共株式会社 | 抗体－吡咯并苯并二氮杂卓衍生物偶联物 |
| TW201938194A (zh) | 2017-12-05 | 2019-10-01 | 日商中外製藥股份有限公司 | 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子 |
| US20210054076A1 (en) * | 2018-01-05 | 2021-02-25 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| KR102340989B1 (ko) * | 2018-03-28 | 2021-12-20 | 에이비온 주식회사 | 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도 |
| AU2020223293A1 (en) | 2019-02-15 | 2021-08-19 | Integral Molecular, Inc. | Claudin 6 antibodies and uses thereof |
| WO2020168024A1 (en) | 2019-02-15 | 2020-08-20 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
| CN114174340A (zh) * | 2019-03-20 | 2022-03-11 | 加利福尼亚大学董事会 | 密封蛋白-6抗体和药物缀合物 |
| CN114206934A (zh) * | 2019-03-20 | 2022-03-18 | 加利福尼亚大学董事会 | 密封蛋白-6双特异性抗体 |
| WO2021006328A1 (en) | 2019-07-10 | 2021-01-14 | Chugai Seiyaku Kabushiki Kaisha | Claudin-6 binding molecules and uses thereof |
| WO2021129927A1 (en) | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
| CN111087465B (zh) * | 2019-12-24 | 2020-12-08 | 广州医科大学 | 一种针对密蛋白6的抗体偶联药物及应用 |
| JP6971419B2 (ja) | 2020-03-31 | 2021-11-24 | 中外製薬株式会社 | クローディン６を標的とする多重特異性抗原結合分子およびその使用 |
| AU2021374036A1 (en) * | 2020-11-06 | 2023-06-08 | Amgen Inc. | Polypeptide constructs selectively binding to cldn6 and cd3 |
| CN117157319A (zh) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | 结合cd3和cldn6的异二聚抗体 |
| US20230008868A1 (en) * | 2021-07-08 | 2023-01-12 | Nippon Telegraph And Telephone Corporation | User authentication device, user authentication method, and user authentication computer program |
| WO2023053282A1 (ja) | 2021-09-29 | 2023-04-06 | 中外製薬株式会社 | がんの治療に用いるための細胞傷害誘導治療剤 |
| WO2023064899A1 (en) * | 2021-10-14 | 2023-04-20 | Health Research, Inc. | Compositions and methods for use of recombinant t cell receptors against claudin 6 |
| WO2024046572A1 (en) | 2022-09-01 | 2024-03-07 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
| WO2023105005A1 (en) | 2021-12-09 | 2023-06-15 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
| CN116064622B (zh) * | 2023-02-13 | 2023-10-13 | 优睿赛思(武汉)生物科技有限公司 | Claudin6-mCherry报告基因CHO-K1稳转细胞株制备及应用 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946788A (en) | 1985-06-11 | 1990-08-07 | Ciba-Geigy Corporation | Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
| US5830755A (en) | 1995-03-27 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | T-cell receptors and their use in therapeutic and diagnostic methods |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| WO2002008288A2 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| WO2000078961A1 (en) | 1999-06-23 | 2000-12-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US5928631A (en) | 1997-06-09 | 1999-07-27 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins |
| US20020127584A1 (en) | 1997-09-18 | 2002-09-12 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US5932445A (en) | 1997-11-07 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Signal peptide-containing proteins |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| NZ531664A (en) | 1998-09-01 | 2005-07-29 | Genentech Inc | Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family |
| AU773028B2 (en) * | 1998-11-03 | 2004-05-13 | Adherex Technologies Inc. | Compounds and methods for modulating claudin-mediated functions |
| AU3124000A (en) | 1998-12-17 | 2000-07-03 | Human Genome Sciences, Inc. | 47 human secreted proteins |
| JP2002536995A (ja) | 1999-02-22 | 2002-11-05 | インサイト・ファーマスーティカルズ・インコーポレイテッド | 結腸の疾患に関連する遺伝子 |
| ES2287020T3 (es) | 1999-06-02 | 2007-12-16 | Genentech, Inc. | Procedimiento y composiciones para inhibir el crecimiento de celulas neoplasicas. |
| EP1514933A1 (en) | 1999-07-08 | 2005-03-16 | Research Association for Biotechnology | Secretory protein or membrane protein |
| EP1242443A4 (en) | 1999-12-23 | 2005-06-22 | Nuvelo Inc | NEW NUCLEIC ACIDS AND POLYPEPTIDES |
| WO2001051513A2 (en) | 2000-01-14 | 2001-07-19 | Corixa Corporation | Ovarian tumor-associated sequences |
| CA2404890C (en) | 2000-03-30 | 2013-11-19 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP2004506413A (ja) | 2000-06-23 | 2004-03-04 | ジェネンテック・インコーポレーテッド | 血管形成に関与する疾患の診断と治療のための組成物と方法 |
| CA2416538A1 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| EP2044839A3 (en) | 2000-08-03 | 2009-07-01 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
| ES2295228T3 (es) | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| KR100788092B1 (ko) | 2001-06-20 | 2007-12-21 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
| CA2379661A1 (en) | 2002-03-28 | 2003-09-28 | Kursad Turksen | Paracellular drug delivery system |
| EP2011886A3 (en) | 2002-04-16 | 2009-02-11 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| AU2003225009A1 (en) * | 2002-04-22 | 2003-11-03 | Dyax Corporation | Antibodies specific for mucin polypeptide |
| US20070207142A1 (en) | 2002-05-08 | 2007-09-06 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| JP2006516089A (ja) | 2002-10-02 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| EP1578996A4 (en) | 2002-10-18 | 2007-12-19 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS |
| AT500651B9 (de) | 2003-05-27 | 2010-04-15 | Altropus Gmbh | Aktiv immunisierender antikörper |
| BRPI0410875A (pt) | 2003-05-30 | 2006-07-04 | Centocor Inc | método de inibição do crescimento de tumor com anticorpos de fator antitecido |
| US20060019256A1 (en) | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2006033664A1 (en) | 2004-03-08 | 2006-03-30 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| US7431927B2 (en) | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
| DE102005025041A1 (de) | 2005-05-30 | 2006-12-07 | Bell Flavors & Fragrances Duft Und Aroma Gmbh | Mittel zur Anwendung in Spülmaschinen sowie Vorrichtung für dessen dosierte Einbringung während der Spül- und Trocknungsphasen |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1970384A1 (en) * | 2007-03-14 | 2008-09-17 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| EP2138576A4 (en) | 2007-03-16 | 2011-02-23 | Kyowa Hakko Kirin Co Ltd | ANTI-CLAUDIN-4 ANTIBODY |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| WO2009025759A1 (en) | 2007-08-17 | 2009-02-26 | Progenics Pharmaceuticals (Nevada), Inc. | Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof |
| WO2009028663A1 (ja) * | 2007-08-30 | 2009-03-05 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-3抗体 |
| EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
| KR20100116179A (ko) * | 2008-01-11 | 2010-10-29 | 고쿠리츠다이가쿠호우진 도쿄다이가쿠 | 항-ｃｌｄｎ6 항체 |
| CA2721072A1 (en) | 2008-04-11 | 2009-10-15 | Bionovo, Inc. | Anticancer methods employing extracts of gleditsia sinensis lam |
| WO2010043650A2 (en) | 2008-10-14 | 2010-04-22 | Ablynx Nv | Amino acid sequences directed against cellular receptors for viruses and bacteria |
| DE102009026966A1 (de) | 2008-12-18 | 2010-07-01 | Robert Bosch Gmbh | Betrieb eines Bremskraftverstärkers als Pedalsimulator |
| JP2010178650A (ja) | 2009-02-04 | 2010-08-19 | Univ Of Tokyo | 固形癌の再発予測のための試験方法および再発予防剤 |
| EP2221063A1 (en) | 2009-02-20 | 2010-08-25 | Ganymed Pharmaceuticals AG | Methods and compositions for diagnosis and treatment of cancer |
| CN107028969A (zh) | 2009-02-20 | 2017-08-11 | 加尼梅德药物公司 | 用于癌症诊断和治疗的方法和组合物 |
| LT2499161T (lt) | 2009-11-11 | 2017-11-27 | Ganymed Pharmaceuticals Gmbh | Specifiniai antikūnai, skirti klaudinui 6 (cldn6) |
| EP2322555A1 (en) | 2009-11-11 | 2011-05-18 | Ganymed Pharmaceuticals AG | Antibodies specific for claudin 6 (CLDN6) |
| WO2011105551A1 (ja) | 2010-02-26 | 2011-09-01 | 国立大学法人大阪大学 | 癌幹細胞の検出方法、及び癌の治療剤または再発予防剤 |
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| NZ724296A (en) | 2011-05-13 | 2020-05-29 | Ganymed Pharmaceuticals Ag | Antibodies for treatment of cancer expressing claudin 6 |
| EP2749641B1 (en) | 2011-09-07 | 2021-06-02 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell isolation |
| EP2605017A1 (de) | 2011-12-16 | 2013-06-19 | Protagen AG | Markersequenzen für gynäkologisches Malignom und deren Verwendung |
| WO2014015148A1 (en) | 2012-07-19 | 2014-01-23 | Amgen Inc. | Human btnl3 proteins, nucleic acids, and antibodies and uses thereof |
| WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
-
2012
- 2012-04-20 NZ NZ724296A patent/NZ724296A/en not_active IP Right Cessation
- 2012-04-20 CN CN201710009470.8A patent/CN107011440B/zh active Active
- 2012-04-20 RS RS20181513A patent/RS58087B1/sr unknown
- 2012-04-20 UA UAA201314474A patent/UA115969C2/uk unknown
- 2012-04-20 RU RU2013155455A patent/RU2676731C2/ru active
- 2012-04-20 UA UAA201708784A patent/UA127584C2/uk unknown
- 2012-04-20 CN CN201710009512.8A patent/CN107090043B/zh active Active
- 2012-04-20 CA CA2832174A patent/CA2832174C/en active Active
- 2012-04-20 EP EP12715856.6A patent/EP2707390B1/en active Active
- 2012-04-20 EP EP15201110.2A patent/EP3026064B1/en active Active
- 2012-04-20 PL PL12715856T patent/PL2707390T3/pl unknown
- 2012-04-20 HU HUE12715856A patent/HUE028603T2/en unknown
- 2012-04-20 CN CN201280022739.1A patent/CN103748112B/zh active Active
- 2012-04-20 DK DK15201110.2T patent/DK3026064T3/en active
- 2012-04-20 WO PCT/EP2012/001721 patent/WO2012156018A1/en active Application Filing
- 2012-04-20 AU AU2012258087A patent/AU2012258087B2/en active Active
- 2012-04-20 ME MEP-2016-39A patent/ME02369B/me unknown
- 2012-04-20 SI SI201230482T patent/SI2707390T1/sl unknown
- 2012-04-20 US US14/117,118 patent/US9321842B2/en active Active
- 2012-04-20 KR KR1020137030171A patent/KR102072183B1/ko active IP Right Grant
- 2012-04-20 NZ NZ741567A patent/NZ741567A/en unknown
- 2012-04-20 SG SG2013070701A patent/SG193551A1/en unknown
- 2012-04-20 KR KR1020207018103A patent/KR102430870B1/ko active IP Right Grant
- 2012-04-20 KR KR1020227026991A patent/KR20220116069A/ko not_active Application Discontinuation
- 2012-04-20 BR BR112013029212A patent/BR112013029212B1/pt active IP Right Grant
- 2012-04-20 PL PL15201110T patent/PL3026064T3/pl unknown
- 2012-04-20 LT LTEP15201110.2T patent/LT3026064T/lt unknown
- 2012-04-20 NZ NZ706004A patent/NZ706004A/en unknown
- 2012-04-20 JP JP2014510679A patent/JP6276176B2/ja active Active
- 2012-04-20 SI SI201231496T patent/SI3026064T1/sl unknown
- 2012-04-20 RS RS20160121A patent/RS54627B1/en unknown
- 2012-04-20 DK DK12715856.6T patent/DK2707390T3/en active
- 2012-04-20 ES ES12715856.6T patent/ES2565063T3/es active Active
- 2012-04-20 EP EP18179328.2A patent/EP3421496A1/en active Pending
- 2012-04-20 MX MX2013013053A patent/MX341147B/es active IP Right Grant
- 2012-05-08 AR ARP120101613A patent/AR086306A1/es active IP Right Grant
-
2013
- 2013-09-20 ZA ZA2013/07102A patent/ZA201307102B/en unknown
- 2013-10-06 IL IL228738A patent/IL228738B/en active IP Right Grant
- 2013-11-08 MX MX2020011778A patent/MX2020011778A/es unknown
- 2013-11-08 MX MX2020011779A patent/MX2020011779A/es unknown
- 2013-11-08 MX MX2020001224A patent/MX2020001224A/es unknown
-
2014
- 2014-08-22 HK HK14108609.0A patent/HK1195320A1/xx unknown
-
2016
- 2016-02-29 HR HRP20160212TT patent/HRP20160212T1/hr unknown
- 2016-03-01 CY CY20161100181T patent/CY1118608T1/el unknown
- 2016-03-04 SM SM201600064T patent/SMT201600064B/xx unknown
- 2016-03-21 US US15/076,536 patent/US10233253B2/en active Active
-
2017
- 2017-07-07 AU AU2017204663A patent/AU2017204663B2/en active Active
-
2018
- 2018-01-11 JP JP2018002528A patent/JP6637083B2/ja active Active
- 2018-07-05 US US16/028,210 patent/US10919974B2/en active Active
- 2018-12-21 CY CY181101393T patent/CY1121085T1/el unknown
-
2019
- 2019-01-03 HR HRP20190014TT patent/HRP20190014T1/hr unknown
- 2019-08-22 AU AU2019219797A patent/AU2019219797B2/en active Active
-
2020
- 2020-12-30 US US17/138,403 patent/US11859008B2/en active Active
-
2021
- 2021-06-28 AR ARP210101787A patent/AR122771A2/es unknown
- 2021-12-03 AU AU2021277764A patent/AU2021277764A1/en active Pending
-
2023
- 2023-04-12 JP JP2023064843A patent/JP2023089133A/ja active Pending
- 2023-11-27 US US18/520,264 patent/US20240101703A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2565063T3 (es) | Anticuerpos para el tratamiento de un cáncer que expresa la claudina 6 | |
| Mohamet et al. | Loss of function of e-cadherin in embryonic stem cells and the relevance to models of tumorigenesis | |
| Rivlin et al. | p53 orchestrates between normal differentiation and cancer | |
| CO2017002378A2 (es) | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) | |
| Mathews et al. | Epigenetic gene regulation in stem cells and correlation to cancer | |
| MX347150B (es) | Anticuerpos especificos para claudina 6 (cldn6). | |
| AR070865A1 (es) | Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso | |
| Barati et al. | Pluripotent stem cells: cancer study, therapy, and vaccination | |
| Benton et al. | Laminin‐1 induces E‐cadherin expression in 3‐dimensional cultured breast cancer cells by inhibiting DNA methyltransferase 1 and reversing promoter methylation status | |
| RU2015143106A (ru) | Терапия злокачественных опухолей | |
| Nibhoria et al. | A clinicopathological and immunohistochemical correlation in cutaneous metastases from internal malignancies: a five-year study | |
| Maddipati et al. | KLF4 initiates acinar cell reprogramming and is essential for the early stages of pancreatic carcinogenesis | |
| Misdraji | Tumours of the appendix | |
| Pereira et al. | Peritoneal carcinomatosis: A malignant disease with an embryological origin? | |
| Wijaya et al. | Reversing breast cancer stem cell into breast somatic stem cell | |
| AR081065A1 (es) | Peptidos ect2 (secuencia 2 de transformacion de la celula epitelial) y vacunas que los incluyen | |
| 吉田雄一 et al. | Malignant peripheral nerve sheath tumour arising from solitary sclerotic neurofibroma | |
| Sabol | Next generation sequencing of small RNA in head and neck cancer | |
| Schoenborn | Characterization of Tumor Suppressor PKP1 in Neoplastic Progression of Barrett | |
| Geraci et al. | Carcinoma showing thymus-like differentiation (CASTLE) | |
| Mariano et al. | Papillary mucinous cystadenocarcinoma: rare malignant tumor in minor salivary gland | |
| de Mendonça et al. | Mucosal Melanoma of the Head and Neck: From Diagnosis to Treatment | |
| Serramia | Cistoadenoma papilar de epidídimo | |
| Chen | OCT4-NANOG Promotes Lung Cancer Oncogenesis through Induction of Epithelial-Mesenchymal Transdifferentiations. | |
| 赵士锋 et al. | Expressions of Oct-4, SOX2 and KPNA2 in triple-negative breast cancer and their clinical significance |